Skip to main content

York Charles N II's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed May 17, 2024

Accession no.
0001415889-24-013616
Filed
May 17, 2024
Trade date
May 15-16, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $43.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
York Charles N IICIK 0001655962Officer (COO, CFO AND SECRETARY)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2024Common StockMOption exerciseAcquired+1,375––218,668Direct
May 15, 2024Common StockMOption exerciseAcquired+2,250––220,918Direct
May 15, 2024Common StockMOption exerciseAcquired+6,625––227,543Direct
May 16, 2024Common StockSSaleDisposed−2,675$16.08−$43,014224,868Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 15, 2024Common StockMOption exerciseDisposed−1,375$0.00$08,250Direct
May 15, 2024Common StockMOption exerciseDisposed−2,250$0.00$022,500Direct
May 15, 2024Common StockMOption exerciseDisposed−6,625$0.00$092,750Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)